Chi Sheng Pharma & Biotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Chi Sheng Pharma & Biotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	48.0%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Apr 06

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Mar 10

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 01

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Jan 05

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Dec 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chi Sheng Pharma & Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:4111 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	1,082	73	24	132	N/A
3/31/2024	1,065	73	-67	47	N/A
12/31/2023	1,061	69	-27	75	N/A
9/30/2023	1,090	116	9	111	N/A
6/30/2023	1,115	151	89	197	N/A
3/31/2023	1,130	164	107	225	N/A
12/31/2022	1,143	179	109	215	N/A
9/30/2022	1,105	186	128	216	N/A
6/30/2022	1,085	150	-73	197	N/A
3/31/2022	1,059	129	-100	164	N/A
12/31/2021	1,022	108	-126	139	N/A
9/30/2021	1,003	56	-137	125	N/A
6/30/2021	971	41	61	103	N/A
3/31/2021	953	46	87	109	N/A
12/31/2020	979	59	121	144	N/A
9/30/2020	1,005	72	101	129	N/A
6/30/2020	1,026	80	152	177	N/A
3/31/2020	1,047	85	179	206	N/A
12/31/2019	1,023	72	126	163	N/A
9/30/2019	998	57	131	187	N/A
6/30/2019	985	57	69	134	N/A
3/31/2019	964	46	18	87	N/A
12/31/2018	967	42	38	114	N/A
9/30/2018	985	52	34	98	N/A
6/30/2018	1,016	60	63	133	N/A
3/31/2018	1,032	69	N/A	157	N/A
12/31/2017	1,045	82	N/A	181	N/A
9/30/2017	1,034	91	N/A	162	N/A
6/30/2017	1,012	88	N/A	160	N/A
3/31/2017	995	85	N/A	133	N/A
12/31/2016	964	73	N/A	104	N/A
9/30/2016	946	48	N/A	130	N/A
6/30/2016	936	46	N/A	120	N/A
3/31/2016	938	42	N/A	116	N/A
12/31/2015	932	39	N/A	97	N/A
9/30/2015	908	40	N/A	92	N/A
6/30/2015	922	50	N/A	89	N/A
3/31/2015	925	59	N/A	116	N/A
12/31/2014	943	73	N/A	147	N/A
9/30/2014	979	104	N/A	167	N/A
6/30/2014	974	105	N/A	177	N/A
3/31/2014	960	106	N/A	188	N/A
12/31/2013	921	96	N/A	143	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4111's forecast earnings growth is above the savings rate (1%).

Earnings vs Market: Insufficient data to determine if 4111's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4111's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4111's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4111's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4111's Return on Equity is forecast to be high in 3 years time

Chi Sheng Pharma & Biotech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.36 (vs NT$0.36 in 2Q 2023)

Dividend reduced to NT$1.00

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 23%

Now 28% overvalued after recent price rise

First quarter 2024 earnings released: EPS: NT$0.41 (vs NT$0.33 in 1Q 2023)

Full year 2023 earnings released: EPS: NT$1.21 (vs NT$3.15 in FY 2022)

Chi Sheng Pharma & Biotech Co., Ltd, Annual General Meeting, Jun 13, 2024

New minor risk - Profit margin trend

Upcoming dividend of NT$1.20 per share at 4.5% yield

Second quarter 2023 earnings released: EPS: NT$0.36 (vs NT$0.46 in 2Q 2022)

Investor sentiment improves as stock rises 24%

Full year 2022 earnings released: EPS: NT$3.14 (vs NT$1.42 in FY 2021)

Investor sentiment improved over the past week

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released: EPS NT$0.39 (vs NT$0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.21 (vs NT$0.28 in 2Q 2020)

Upcoming dividend of NT$1.00 per share

First quarter 2021 earnings released: EPS NT$0.22 (vs NT$0.46 in 1Q 2020)

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Full year 2020 earnings released: EPS NT$1.04 (vs NT$1.27 in FY 2019)

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$22.80

New 90-day low: NT$23.30

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Third quarter 2020 earnings released: EPS NT$0.14

New 90-day low: NT$24.00

New 90-day low - NT$24.40

First half earnings released

First half earnings released

New 90-day low - NT$25.55

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies